Alzheimer's Assocation Research only
All of
  • Go to
  • Research Center
  • AAIC
  • Journal
  • Grants
  • TrialMatch
  • Press
  • Donate
  • Contact Us
Science and Progress
Clinical Trials
Funding and Collaboration
You can Help
Stay Current
Video and Resources

Text Size

Small text Medium text Large text

Research Grants 2008

To view an abstract, select an author from the vertical list on the left side.

2008 Grants - Goodwin

Gamma-Secretase Inhibitors Induce Cell Cycle Defects and Chromosome Aneuploidy

Bonnie Goodwin, Ph.D.
University of South Florida
Tampa, Florida

2008 New Investigator Research Grant

Gamma-secretase is a cluster of enzymes that has been a focus of research on the causes of Alzheimer's disease. The enzyme cluster plays a role in cutting amyloid precursor proteins (APP) into beta-amyloid fragments, key suspects in Alzheimer pathology. Furthermore, genetic defects in components of gamma-secretase, notably the protein presenilin-1 (PS1), have been linked to inherited forms of Alzheimer's disease. Thus, inhibition of gamma-secretase is a potential strategy for slowing the progression of Alzheimer's disease. However, gamma-secretase performs other important functions in cells.

Bonnie Goodwin, Ph.D., and colleagues are studying the role of gamma-secretase and the effects of gamma-secretase inhibitors in nerve cells and other cells. They have found that PS1 interacts with the cells' genetic material (chromosomes) and that inherited mutations in PS1 can lead to chromosomal abnormalities. These observations suggest that PS1 mutations associated with some forms of Alzheimer's disease may cause genetic abnormalities in cells that give rise to nerve cells.

Similar to PS1 mutations, inhibitors of the gamma-secretase complex (which contains PS1) caused genetic abnormalities in cells and affected the ability of the cells to divide normally. Some of these effects were dependent on the presence of APP. Dr. Goodwin and colleagues plan to further study the effects of gamma-secretase inhibitors, focusing on inhibitors that specifically inhibit the ability of the enzyme complex to cut APP. They will also study how APP and beta-amyloid influence the effects of gamma-secretase inhibitors. These studies may provide important insights into the potential use of gamma-secretase inhibitors for treatment of Alzheimer's disease.

Alzheimer's Association International Conference | July 16-20, 2017, London, England

Abstract Submissions Now Open

The Scientific Program Committee is now accepting submissions for poster
presentations, oral presentations and featured research sessions.